RETRACTED: Wiesinger et al. An Innovative Tool for Evidence-Based, Personalized Treatment Trials in Mucopolysaccharidosis. Pharmaceutics 2023, 15, 1565
Pharmaceutics. 2023 Nov 7;15(11):2596.
doi: 10.3390/pharmaceutics15112596.
1 Institute of Congenital Metabolic Diseases, Paracelsus Medical University, 5020 Salzburg, Austria.
2 European Reference Network for Hereditary Metabolic Diseases, MetabERN, 33100 Udine, Italy.
3 Stem Cell and Neurotherapies, Division of Cell Matrix Biology and Regenerative Medicine, Faculty of Biology, Medicine and Health, University of Manchester, Manchester M13 9PL, UK.
4 Department of Genetics, Medical Genetics Service and Biodiscovery Laboratory, Portal Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul (UFRGS), Casa dos Raros, Porto Alegre 90610-261, Brazil.
5 Department of Child Neurology, Epilepetology and Social Pediatrics, Center of Rare Diseases, University Hospital Giessen/Marburg, 35392 Giessen, Germany.
6 Regional Coordinating Center for Rare Diseases, University Hospital Udine, 33100 Udine, Italy.
7 Department of Neurology, Christian Doppler University Hospital, Paracelsus Medical University, 5020 Salzburg, Austria.
8 Department of Pediatric Cardiology, University Hospital Mainz, 55131 Mainz, Germany.
9 Team Biostatistics and Big Medical Data, IDA Lab Salzburg, Paracelsus Medical University, 5020 Salzburg, Austria.
10 Research and Innovation Management, Paracelsus Medical University, 5020 Salzburg, Austria.